Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | Finanzwire

Basculer en Français

9473	Companies
185399	Keywords
117755	Articles
99281	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 01/06/2025 at 22:10, 10 months 29 days ago

Protagonist Therapeutics Announces Inducement Awards to New Executive

Stock Options Nasdaq Protagonist Therapeutics Inducement Awards New Executive
PRESS RELEASE

published on 01/06/2025 at 22:05, 10 months 29 days ago

Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics grants inducement awards to Dr. Newman Yeilding for the role of Executive Vice President, Chief Scientific Officer, under inducement plan. Company's focus on peptide therapeutics and Phase 3 drug development

Protagonist Therapeutics Phase 3 Clinical Development Inducement Awards Peptide Therapeutics Drug Candidates
BRIEF

published on 12/19/2024 at 22:10, 11 months 16 days ago

Protagonist Therapeutics to Present at J.P. Morgan Healthcare Conference

Protagonist Therapeutics Rusfertide Icotrokinra Biopharmaceutical Development J.P. Morgan Conference
PRESS RELEASE

published on 12/19/2024 at 22:05, 11 months 16 days ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Protagonist Therapeutics to present company overview at 43rd Annual J.P. Morgan Healthcare Conference. Highlights late-stage peptides in clinical development

Clinical Development Biopharmaceutical Protagonist Therapeutics J.P. Morgan Healthcare Conference Peptides
BRIEF

published on 12/09/2024 at 22:10, 11 months 26 days ago

Protagonist Therapeutics Reveals Promising Rusfertide Study Results at ASH 2024

Rusfertide Polycythemia Vera Phase 2 REVIVE Hematocrit Control ASH 2024
PRESS RELEASE

published on 12/09/2024 at 22:05, 11 months 26 days ago

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Protagonist Therapeutics announced positive final data from rusfertide Phase 2 REVIVE study for treating polycythemia vera, presented at ASH 2024

Protagonist Therapeutics Rusfertide Polycythemia Vera Hematocrit Control REVIVE Study
BRIEF

published on 11/22/2024 at 13:35, 1 year ago

Protagonist Therapeutics to Engage at Evercore ISI HealthCONx Conference

Clinical Trials Protagonist Therapeutics Conference Participation Evercore ISI HealthCONx Biopharmaceutical Development
PRESS RELEASE

published on 11/22/2024 at 13:30, 1 year ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Protagonist Therapeutics to participate in fireside chat at 7th Annual Evercore ISI HealthCONx Conference on Dec 3-5, 2024. Company's CEO, Dinesh V. Patel, to discuss latest developments

Biopharmaceutical Fireside Chat Protagonist Therapeutics Evercore ISI HealthCONx Conference Dinesh V. Patel
BRIEF

published on 11/21/2024 at 22:10, 1 year ago

Protagonist Therapeutics Nominates PN-881 for Immune-Mediated Skin Disorders

Protagonist Therapeutics IL-17 Antagonist PN-881 Skin Diseases Phase I Trials
PRESS RELEASE

published on 11/21/2024 at 22:05, 1 year ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics announces selection of PN-881, an oral peptide interleukin-17 antagonist, as a development candidate for immune-mediated skin diseases. IND enabling studies ongoing with Phase I expected in Q425

Protagonist Therapeutics IL-17 Antagonist PN-881 Oral Peptide Immune-mediated Skin Diseases

Accesswire

Published on 12/05/2025 at 02:35, 6 hours 23 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 28 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 58 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 53 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 58 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 08:30, 27 minutes ago

Dahua Technology Celebrates Pro Challenge 2025 to Deepen Global Installer Ecosystem Collaboration
Published on 12/05/2025 at 08:30, 28 minutes ago

Premier Miton Global Renewables Trust PLC - Suspension
Published on 12/05/2025 at 08:05, 52 minutes ago

Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 57 minutes ago

Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 57 minutes ago

Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025

Les Echos

Published on 12/05/2025 at 08:45, 13 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 14 hours 58 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 15 hours 13 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 15 hours 13 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE